drugset
drugset / Trial / NCT03513601

Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma

NCT03513601 ↗

Phase 4 Unknown 20 enrolled Mingzhi Zhang
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To explore the clinical features and efficacy evaluation of large b-cell lymphoma in old age.

Timeline

Start
2017-07-01
Primary completion
2019-05
Completion
2019-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Subject Epirubicin Small molecule 50 mg/m2 Intravenous
Background Prednisone Other / unclassified 60 mg Oral
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Background Vincristine Small molecule 2 mg Intravenous

Indications

diffuse large B-cell lymphoma